BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30180865)

  • 1. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
    Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
    Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.
    Dengler MA; Weilbacher A; Gutekunst M; Staiger AM; Vöhringer MC; Horn H; Ott G; Aulitzky WE; van der Kuip H
    Cell Death Dis; 2014 Jan; 5(1):e1013. PubMed ID: 24457957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
    Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
    Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
    BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
    Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
    Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
    Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Weniger MA; Overbey J; Dunleavy K; Wilson WH; Wiestner A; Parekh S
    Oncotarget; 2015 Sep; 6(29):27332-42. PubMed ID: 25714012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
    Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
    Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
    Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
    Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
    Wang K; Huang X; Di Liberto M; Chen-Kiang S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):809-823. PubMed ID: 32861279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
    Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
    Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
    Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
    Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
    Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
    Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Marzec M; Kasprzycka M; Lai R; Gladden AB; Wlodarski P; Tomczak E; Nowell P; Deprimo SE; Sadis S; Eck S; Schuster SJ; Diehl JA; Wasik MA
    Blood; 2006 Sep; 108(5):1744-50. PubMed ID: 16690963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.